Video Interview: Abeona Breaking Into Rare Diseases

Three-year-old Abeona Therapeutics is poised to enter the clinic with its lead gene therapy programs targeting some devastating lysosomal diseases.

Three-year-old Abeona Therapeutics is poised to enter the clinic with its lead gene therapy programs targeting some devastating lysosomal diseases.

In collaboration with patient advocate groups, researchers and clinicians, Abeona President and CEO Tim Miller tells Informa Pharma Insights global...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip